Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.61 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625535 | 0.89 | SMN1; SMN2 (0.64) | CHRM2PDCD1CD274SMN1; SMN2ALDH1A1 | |
| SCHEMBL7964319 | 0.88 | CHRM2 (0.71) | CHRM2PDCD1CD274SMN1; SMN2CA12 | |
| SCHEMBL4919923 | 0.86 | CHRM2 (0.75) | CHRM2SMN1; SMN2ALDH1A1CA12CA1 | |
| SCHEMBL4913672 | 0.84 | CHRM2 (0.79) | CHRM2CA12CA1CA2CA9 | |
| SCHEMBL5032223 | 0.84 | CHRM2 (0.79) | CHRM2CA12CA1CA2CA9 | |
| SCHEMBL4917450 | 0.84 | CHRM2 (0.79) | CHRM2CA12CA1CA2CA9 | |
| SCHEMBL8252697 | 0.83 | L3MBTL1 (0.56) | CHRM2PDCD1CD274SMN1; SMN2ALDH1A1 | |
| SCHEMBL13853400 | 0.82 | CHRM2 (0.57) | CHRM2SMN1; SMN2ALDH1A1CA12CA1 | |
| SCHEMBL842161 | 0.81 | CHRM2 (0.67) | CHRM2SMN1; SMN2ALDH1A1CA12CA1 | |
| SCHEMBL11881942 | 0.80 | CA1 (0.69) | CHRM2ALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189803-B2 | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2837624-B1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | ZHEJIANG HISUN PHARM CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-9676736-B2 | 4-substituent-2-hydroxylmorpholine-3-one and preparation method thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-13 | — | — | US | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| EP-2440554-B1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | MERCK SERONO SA (CH) | 2016-10-05 | — | — | EP | disclosed |
| US-20150087828-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2837624-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2015-02-18 | — | — | EP | disclosed |
| WO-2014086927-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | WO | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20080027060-A1 | DIPEPTIDE NITRILES | ALTMANN EVA | 2008-01-31 | — | — | US | disclosed |
| US-20080027060-A1 | DIPEPTIDE NITRILES | ALTMANN EVA | 2008-01-31 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-6288224-B1 | Preparation of n-arylmethyl aziridine derivatives, 1,4,7,10-tetraazacyclododecane derivatives obtained therefrom and n-arylethyl-ethanolamine sulphonate esters as intermediates | NYCOMED SALUTAR, INC. | 2001-09-11 | — | — | US | disclosed |
| US-6048979-A | CYCLOTETRAMERIZING, CLEAVAGE OF ARYLMETHYL GROUPS TO PREPARE CYCLEN AND DERIVATIVES | NYCOMED SALUTAR, INC. (US) | 2000-04-11 | — | — | US | disclosed |
| CN-1181751-A | Prepn. of N-arylmethyl axiridine derivatives, 1, 4, 7, 10 -Tetraazacyclododecane derivatives obtained therefrom and N -arylmethyl -ethanol -amine sulphonate esters as intermediates | NYCOMED SALUTAR INC (US) | 1998-05-13 | — | — | CN | disclosed |
| EP-0813523-A2 | PREPARATION OF N-ARYLMETHYL AZIRIDINE DERIVATIVES, 1,4,7,10-TETRAAZACYCLODODECANE DERIVATIVES OBTAINED THEREFROM AND N-ARYLMETHYL-ETHANOL-AMINE SULPHONATE ESTERS AS INTERMEDIATES | NYCOMED SALUTAR, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1996028420-A2 | PREPARATION OF N-ARYLMETHYL AZIRIDINE DERIVATIVES, 1,4,7,10-TETRAAZACYCLODODECANE DERIVATIVES OBTAINED THEREFROM AND N-ARYLMETHYL-ETHANOL-AMINE SULPHONATE ESTERS AS INTERMEDIATES | NYCOMED SALUTAR, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | CHRM2 4864/4885PDCD1 1450/4885CD274 581/4885 |
| US-20150087828-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | OPRK1, HTR3C, HTR3A | CHRM2 246/4885PDCD1 1047/4885CD274 445/4885 |
| US-10189803-B2 | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions | AZI2, ABL1, DHPS | CHRM2 4638/4885PDCD1 962/4885CD274 2348/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | CHRM2 2310/4885PDCD1 2448/4885CD274 3877/4885 |
| US-20080027060-A1 | DIPEPTIDE NITRILES | CTSL, CTSS, CTSB | CHRM2 680/4885PDCD1 4584/4885CD274 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.